## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (31% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($559.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026**
- Source: The AI Journal | 20251226T131716 | Neutral | Relevance: 100%
- Thermo Fisher Scientific Inc. (NYSE: TMO) announced it would release its financial results for Q4 and full year 2025 before market open on Thursday, January 29, 2026. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss its financial performance and future expectations. The call will be webcast live on the "Investors" section of their website.

**2. Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026**
- Source: The Joplin Globe | 20251226T130829 | Neutral | Relevance: 100%
- Thermo Fisher Scientific Inc. (NYSE: TMO) announced it will release its financial results for the fourth quarter and full year 2025 before market open on Thursday, January 29, 2026. The company will hold a conference call on the same day at 8:30 a.m. ET to discuss its financial performance and future expectations. A replay of the call will be available until Wednesday, April 22, 2026.

**3. Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026**
- Source: Business Wire | 20251226T130221 | Neutral | Relevance: 100%
- Thermo Fisher Scientific Inc. (NYSE: TMO) announced it will release its fourth quarter and full-year 2025 financial results before market open on Thursday, January 29, 2026. A conference call to discuss these results and future expectations will be held on the same day at 8:30 a.m. ET. The call will be webcast live on the "Investors" section of their website, www.thermofisher.com.

**4. Thermo Fisher Scientific (TMO) Stock After the Bell on Dec. 24, 2025: What Happened Today and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251225T024509 | Neutral | Relevance: 100%
- Thermo Fisher Scientific (TMO) closed the shortened Christmas Eve session on December 24, 2025, with a slight dip amidst low trading volume. Key takeaways for investors include a decrease in short interest, indicating reduced bearish sentiment, contrasting with an "Ultra Expensive" valuation assessment by AAII. Analysts maintain a constructive view with price targets significantly above the current stock price, driven by strategic acquisitions and capital return programs.

**5. NovaPoint Capital LLC Takes $1.10 Million Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251228T120457 | Bullish | Relevance: 100%
- NovaPoint Capital LLC recently acquired a new stake of 2,269 shares in Thermo Fisher Scientific Inc., valued at approximately $1.10 million. This comes as other institutional investors have also adjusted their positions in the medical research company. Thermo Fisher Scientific has reported strong earnings, initiated a stock repurchase plan, and declared a quarterly dividend.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Momentum building: MRS_20 improving +2.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 23.6x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.2B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 23.6 |
| Current P/E | 25.6 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.9% to 0.1% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. Volume at 31% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.15% (CS: 55) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.199x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $580.78
- **Stop Loss:** $559.44 (3.7% risk)
- **Target:** $602.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $35,427.58
- **Portfolio %:** 35.43%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*